2.07
price down icon7.21%   -0.15
after-market アフターアワーズ: 2.08 0.01 +0.48%
loading
前日終値:
$2.22
開ける:
$2.23
24時間の取引高:
1.98M
Relative Volume:
1.24
時価総額:
$239.75M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.9539
EPS:
-2.17
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-0.96%
1か月 パフォーマンス:
-34.60%
6か月 パフォーマンス:
-44.32%
1年 パフォーマンス:
-15.92%
1日の値動き範囲:
Value
$2.01
$2.2799
1週間の範囲:
Value
$1.96
$3.50
52週間の値動き範囲:
Value
$1.96
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1196)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FATE 2.07 239.75M 13.45M -178.23M -132.53M -2.17
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Nov 20, 2024

FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Needham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Fate Thera rockets on early data for FT819 - The Pharma Letter

Nov 19, 2024
pulisher
Nov 18, 2024

Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Fate Therapeutics Unveils Q3 2024 Financial Highlights - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

BMO cuts Fate Therapeutics stock target, keeps market rating on initial data - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Fate Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 13, 2024
pulisher
Nov 12, 2024

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times

Nov 12, 2024
pulisher
Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - The Manila Times

Nov 09, 2024
pulisher
Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, - GlobeNewswire

Nov 09, 2024
pulisher
Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewswire Inc.

Nov 09, 2024
pulisher
Nov 08, 2024

Fate Therapeutics Presents Pan-tumor Targeting Preclinical - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Fate Therapeutics Inc (FATE) Worth Considering For The Next Few Weeks - Stocks Register

Nov 07, 2024
pulisher
Nov 07, 2024

Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register

Nov 07, 2024
pulisher
Nov 04, 2024

Global T-cell Therapy Market Trend [2024-2032] | Consumer Demographics - WICZ

Nov 04, 2024
pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024
pulisher
Oct 25, 2024

Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St

Oct 25, 2024
pulisher
Oct 22, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne

Oct 22, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 14, 2024
pulisher
Oct 09, 2024

Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register

Oct 08, 2024
pulisher
Oct 07, 2024

The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Fate Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Oct 03, 2024

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):